CN105828821B - 具有κ活性的阿片受体拮抗剂和沃替西汀用于治疗具有忧郁特征的抑郁障碍的用途 - Google Patents

具有κ活性的阿片受体拮抗剂和沃替西汀用于治疗具有忧郁特征的抑郁障碍的用途 Download PDF

Info

Publication number
CN105828821B
CN105828821B CN201480069586.5A CN201480069586A CN105828821B CN 105828821 B CN105828821 B CN 105828821B CN 201480069586 A CN201480069586 A CN 201480069586A CN 105828821 B CN105828821 B CN 105828821B
Authority
CN
China
Prior art keywords
vortioxetine
nalmefene
active
treatment
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480069586.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN105828821A (zh
Inventor
C·S·莫里洛
G·N·斯梅金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52146489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105828821(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of CN105828821A publication Critical patent/CN105828821A/zh
Application granted granted Critical
Publication of CN105828821B publication Critical patent/CN105828821B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480069586.5A 2013-12-20 2014-12-18 具有κ活性的阿片受体拮抗剂和沃替西汀用于治疗具有忧郁特征的抑郁障碍的用途 Active CN105828821B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201300710 2013-12-20
DKPA201300710 2013-12-20
DKPA201400590 2014-10-16
DKPA201400590 2014-10-16
PCT/EP2014/078515 WO2015091833A1 (en) 2013-12-20 2014-12-18 Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features

Publications (2)

Publication Number Publication Date
CN105828821A CN105828821A (zh) 2016-08-03
CN105828821B true CN105828821B (zh) 2019-04-09

Family

ID=52146489

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480069586.5A Active CN105828821B (zh) 2013-12-20 2014-12-18 具有κ活性的阿片受体拮抗剂和沃替西汀用于治疗具有忧郁特征的抑郁障碍的用途

Country Status (14)

Country Link
US (1) US10376506B2 (enExample)
EP (1) EP3082815B1 (enExample)
JP (1) JP6448645B2 (enExample)
KR (1) KR20160093025A (enExample)
CN (1) CN105828821B (enExample)
AU (1) AU2014368548B2 (enExample)
CA (1) CA2933733A1 (enExample)
CL (1) CL2016001570A1 (enExample)
ES (1) ES2694352T3 (enExample)
IL (1) IL246253A0 (enExample)
MX (1) MX368870B (enExample)
RU (1) RU2679661C1 (enExample)
SG (1) SG11201604944PA (enExample)
WO (1) WO2015091833A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018002115A1 (en) 2016-07-01 2018-01-04 H. Lundbeck A/S Vortioxetine dosing regimes for fast onset of antidepressant effect
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
WO2020097068A1 (en) * 2018-11-06 2020-05-14 Purdue Pharma L.P. Compositions and methods for opioid antagonist delivery
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
IL315415A (en) 2022-03-07 2024-11-01 Janssen Pharmaceuticals Inc The compositions containing eticarpant
CA3254365A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. POLYMORPHIC FORMS OF ATICAPRANT INTENDED FOR USE IN THE TREATMENT OF MAJOR DEPRESSION

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020091075A1 (en) * 2000-12-21 2002-07-11 Carlezon Wiliam A. Treatment of depression
US20030181475A1 (en) * 2002-03-20 2003-09-25 Euro-Celtique S.A. Method of administering buprenorphine to treat depression
US20070259939A1 (en) * 2006-05-04 2007-11-08 Accelerated Technologies Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
CN101432011A (zh) * 2006-02-27 2009-05-13 亚历山大·米哈洛 通过诱导逆适应调节神经递质系统的方法
CN102014908A (zh) * 2007-11-13 2011-04-13 H.隆德贝克有限公司 具有组合的sert、5-ht3和5-ht1a活性的化合物的治疗用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028612A (en) 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5013740A (en) 1990-03-22 1991-05-07 Hillel Glover Method for treating emotional numbness and coma
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
US20030087896A1 (en) 2001-08-09 2003-05-08 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
WO2003015783A1 (en) * 2001-08-14 2003-02-27 Biotie Therapies Corporation Method of treating alcoholism or alcohol abuse
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
WO2007064586A1 (en) * 2005-11-28 2007-06-07 Orexigen Therapeutics, Inc. Methods of treating anxiety disorders
WO2008066916A1 (en) 2006-11-30 2008-06-05 The Mclean Hospital Corporation Methods for the treatment of mood disorders
RS51211B (sr) * 2006-04-04 2010-12-31 Emodis Gmbh. Primena formulacija koje sadrže kapa-opioid receptor-agoniste za tretman disocijativnih poremećaja
EP2439201B1 (en) 2006-06-16 2013-08-07 H. Lundbeck A/S Compounds with combined sert, 5-ht3 and 5-ht1a activity
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
PL2435439T3 (pl) 2009-05-25 2016-05-31 H Lundbeck As Wytwarzanie chlorowodorku nalmefenu z naltreksonu
WO2011020030A2 (en) * 2009-08-13 2011-02-17 The General Hospital Corporation Methods and compositions to prevent addiction
CA2797812C (en) 2010-04-30 2018-02-20 Takeda Pharmaceutical Company Limited Enteric tablet
AU2011325563B2 (en) 2010-11-05 2015-08-20 H. Lundbeck A/S Method for the manufacturing of naltrexone
US20150342946A1 (en) 2013-01-30 2015-12-03 Pharmorx Therapeutics, Inc. Treatments For Depression And Other Diseases With A Low Dose Agent
JP6416213B2 (ja) 2013-04-17 2018-10-31 ハー・ルンドベック・アクチエゼルスカベット 気分障害患者の治療のためのナルメフェン
CA2909506C (en) 2013-04-17 2021-04-20 H. Lundbeck A/S Nalmefene for treatment of patients with anxiety disorder

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020091075A1 (en) * 2000-12-21 2002-07-11 Carlezon Wiliam A. Treatment of depression
US20030181475A1 (en) * 2002-03-20 2003-09-25 Euro-Celtique S.A. Method of administering buprenorphine to treat depression
CN101432011A (zh) * 2006-02-27 2009-05-13 亚历山大·米哈洛 通过诱导逆适应调节神经递质系统的方法
US20070259939A1 (en) * 2006-05-04 2007-11-08 Accelerated Technologies Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
CN102014908A (zh) * 2007-11-13 2011-04-13 H.隆德贝克有限公司 具有组合的sert、5-ht3和5-ht1a活性的化合物的治疗用途

Also Published As

Publication number Publication date
RU2016123972A (ru) 2018-01-25
RU2679661C1 (ru) 2019-02-12
US20160310488A1 (en) 2016-10-27
WO2015091833A1 (en) 2015-06-25
KR20160093025A (ko) 2016-08-05
AU2014368548A1 (en) 2016-06-30
IL246253A0 (en) 2016-07-31
SG11201604944PA (en) 2016-07-28
US10376506B2 (en) 2019-08-13
JP2016540030A (ja) 2016-12-22
AU2014368548B2 (en) 2019-09-19
EP3082815B1 (en) 2018-10-03
MX368870B (es) 2019-10-21
ES2694352T3 (es) 2018-12-20
CN105828821A (zh) 2016-08-03
JP6448645B2 (ja) 2019-01-09
EP3082815A1 (en) 2016-10-26
MX2016007947A (es) 2016-09-09
CA2933733A1 (en) 2015-06-25
CL2016001570A1 (es) 2016-12-09

Similar Documents

Publication Publication Date Title
CN105828821B (zh) 具有κ活性的阿片受体拮抗剂和沃替西汀用于治疗具有忧郁特征的抑郁障碍的用途
JP2024091801A (ja) 物質乱用の治療方法
Benyamin et al. Opioid complications and side effects
Barber Examining the use of tramadol hydrochloride as an antidepressant.
Gerak et al. Methocinnamox produces long-lasting antagonism of the behavioral effects of µ-opioid receptor agonists but not prolonged precipitated withdrawal in rats
US20160256472A1 (en) Compositions and methods of administering same
Saboory et al. The long‐term effects of neonatal morphine administration on the pentylenetetrazol seizure model in rats: The role of hippocampal cholinergic receptors in adulthood
KR20200103045A (ko) 수면 장애 치료 및 예방
H Rezvani et al. Novel medication targets for the treatment of alcoholism: preclinical studies
US20070053976A1 (en) Novel combination of drugs as antidepressant
Singh et al. Opioid antagonists. I: Pharmacology and rationale for use in treating self-injury
WO2019091870A1 (en) Stimulant abuse-deterrent compositions
EP1942891B1 (en) Novel combination of drugs as antidepressant
HK1229240B (en) Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
HK1229240A1 (en) Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
Benyamina et al. Pharmacological treatments of opiate dependence
Kufahl et al. Potential use of antidepressants as therapies for drug use disorders
Schifano et al. Recreational drugs' scenario and compulsory treatment in the United Kingdom
Lindsey Effects of monoamine transporter blockers on cocaine self-administration: Relation to dopamine transporter occupancy measured by PET in rhesus monkeys. An investigation of substitute agonist therapeutic strategies for cocaine addiction
Saccone Strategies to Improve Opioid Analgesia: Nociceptin Receptor Agonists and Intranasal Delivery in Monkeys.
Salloum et al. Perspectives for New Pharmacological Treatments of Alcoholism and Substance Dependence
KING et al. Medications of Abuse
Knable et al. Pharmacologic Treatments of Cocaine Dependence
JP2020517730A (ja) 心的外傷後ストレス障害を治療するための方法
Patatanian et al. Résumé-vulgarisation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant